A valuable diagnostic tool and therapeutic alternative for standard prostate cancer therapy has recently been proposed as a combination of a radioisotope and an antagonist that targets prostate-specific membrane antigen (PSMA) [71]. This evidence concerns the gene FOLH1 and prostate carcinoma.